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S U M M A R Y
Objective: Surgical site infection (SSI) remains a serious potential complication after cardiac surgery. This
study evaluated the impact of a cyanoacrylate microbial skin sealant (INTEGUSEAL) on the rate of SSI in
cardiac surgery patients.
Methods: Between January 2006 and July 2008, 580 patients underwent cardiac surgery by a single
surgeon (PMD). Standard preoperative skin preparation was performed in 280 patients (control group),
and 300 patients (microbial skin sealant group) received microbial skin sealant in addition to standard
preoperative preparation. Patient characteristics and preoperative and combined pre/intraoperative risk
scores were evaluated. The primary study endpoint was freedom from SSI within 30 days.
Results: Both groups were established in a 15-month period. Carotid artery disease, diabetes mellitus,
congestive heart failure, previous cardiac surgery, and bilateral internal mammary artery use were
signiﬁcantlymore common in the skin sealant group. Preoperative risk scores for the development of SSI
in the two groups were similar. In the skin sealant group, the combined operative risk score for SSI was
signiﬁcantly higher (9.8  4.0 vs. 8.7  3.7; p < 0.001) nevertheless the incidence of SSI was signiﬁcantly
lower (2.3% vs. 6.8%; p = 0.011) than in the control group.
Conclusion: Changing a surgeon’s standard preoperative practice by including a microbial skin sealant
pretreatment signiﬁcantly reduced the rate of SSI.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The incidence of sternal surgical site infection (SSI) reported in
the literature varies from 2% to 20%, with severe deep sternal
wound infection occurring in up to 8% of patients in some reported
series.1–6 Such infections remain a substantial cause of morbidity
and mortality. A number of preventive measures have been
adopted to reduce the risk of SSI, including improvements in
patient and skin preparation, hand hygiene, antibiotic prophylaxis,
operative room management, asepsis and surgical technique, and
postoperative incision care.7 However, as it is impossible to
completely decontaminate the patient’s skin, the risk of wound
contamination and subsequent SSI is always present during
surgery, even under optimal conditions.* Corresponding author. Present address: Oberarzt Herzchirurgie, Herzzentrum
Leipzig, Universita¨t Leipzig, Struempellstr. 39, D-04289 Leipzig, Germany.
Tel.: +49 341 865 251001.
E-mail address: pascal.dohmen@yahoo.de (P.M. Dohmen).
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doi:10.1016/j.ijid.2011.02.004Microbial skin sealant INTEGUSEAL is an innovative approach to
reducing the risk of contamination of the surgical wound by skin
ﬂora throughout the surgical procedure. When applied to the skin
as a liquid during preoperative skin preparation, moisture and
proteins present in the stratum corneum trigger polymerization of
the n-butyl cyanoacrylate. During this process, the compound
bonds to the skin to form a barrier that immobilizes the bacteria
surviving the application of antimicrobial skin preparations before
surgery. The skin sealant wears off gradually as skin exfoliates over
the following 3–7 days.
Towﬁgh et al. were able to show the advantages of thismicrobial
skin sealant in a prospective, randomized, multicenter clinical trial
of patients undergoing an open inguinal hernia repair.8
The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines were used to improve the
quality of this trial.9
This study was performed to evaluate the impact of a
cyanoacrylate microbial skin sealant to extend preventive
measures to reduce SSI in cardiac surgery.ses. Published by Elsevier Ltd. All rights reserved.
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This before/after trial included 580 adult hospitalized patients
undergoing cardiac surgery by a single surgeon (PMD) at the
Department of Cardiovascular Surgery, Charite´ Hospital, Berlin
between January 2006 and July 2008. The study population
included all adult patients of this single surgeon undergoing
cardiac surgery in which cardiopulmonary bypass (CPB) was
needed. Patients operated on without using CPB were excluded.
Operative techniqueswith regard to CPB, cardioplegia, reperfusion,
and anesthesia (hemodynamics, oxygenation, glucose control and
temperature control), as well as postoperative care, were similar in
all patients. All patients received standard institutional preopera-
tive care, and 300 patients (skin sealant group) received a
microbial skin sealant (INTEGUSEAL Microbial Sealant, Kim-
berly-Clark Corp.; http://www.kchealthcare.com) in addition to
the standard preoperative care. The 280 patients who did not
receive the microbial skin sealant comprised the control group.
Each group was established within a period of 15 months to
investigate the inﬂuence of the additional use of a new microbial
skin sealant to reduce SSI after cardiac surgery. This period of time
was chosen in order to be able to include an adequate number of
patients for statistical analysis.
Nosocomial infections were registered and all complications
during follow-up were recorded in the German Nosocomial
Infection Surveillance System (Krankenhaus Infektions Surveil-
lance System, KISS).10 Participation in the surveillance system was
approved by the Institutional Board on the Ethics of Clinical
Studies. Data were de-identiﬁed and grouped according to
demographics including patient characteristics, operative data,
postoperative data, and postoperative complications.
2.1. Risk factors
For each patient, data for the following variables were
collected: age, gender, body mass index (BMI), arterial hyperten-
sion, hyperlipidemia, chronic obstructive pulmonary disease
(COPD), diabetes mellitus, peripheral vessel disease, carotid artery
disease, cerebral vascular accident, chronic renal failure, ejection
fraction, congestive heart failure, acutemyocardial infarct within 1
month, previous bypass surgery, and previous valve surgery.
Priority of the surgical procedure was deﬁned as ‘emergency’
when surgery was performed immediately, ‘urgent’ when per-
formed within 24 h, and ‘elective’ in all other cases. Cardiac
procedures were deﬁned as single coronary artery bypass graft
(CABG), single valve surgery, concomitant procedures, and others.
The intraoperative variables included number of anastomoses, use
of left internal mammary arteries, use of bilateral internal
mammary arteries, duration of CPB, and insertion of an intra-
aortic balloon pump.
2.2. Preoperative treatment
Preoperative preparation was standardized as previously
reported.11 In brief, for patients undergoing elective or urgent
surgery, hair removal was performed by depilatory cream (stable
patients) or clippers (unstable patients) in the afternoon of the day
before surgery. Furthermore stable patients underwent showering
after shaving, as well as on the morning of surgery. In all of the
patients, soap was used. For patients undergoing emergency
surgery, hair was removed using clippers immediately prior to
surgery. Following hair removal, the skin was disinfected using 1%
povidone–iodine in 70% alcohol. Care was taken to allow the
disinfecting solution to dry completely before application of
the microbial skin sealant. In all patients iodine impregnated
drapes were used, except for those allergic to iodine. Antibioticprophylaxis consisted of cefuroxime (before incision and 1.5 g
intravenous every 6 h for two subsequent doses).
2.3. Microbial skin sealant
The skin sealant was applied after preoperative skin prepara-
tion had been completed and 5–10 min before surgery com-
menced. The INTEGUSEAL IS100 applicator was used to apply a
single even layer of skin sealant over an area of approximately
50  25 cm around the sternal incision mark, which was allowed
to dry completely before iodine impregnated drapes were
positioned. In all patients who received this pretreatment, the
microbial skin sealant was used only on the chest incision site and
it was not applied at the saphenous or radial donor sites in cases
undergoing a CABG procedure.
2.4. Intraoperative management
Intraoperative management was performed as previously
published.12 Optimal temperature was maintained in each patient
during and after surgery. Glycemic control was monitored in all
patients and, if needed, insulin was administered intermittently or
continuously by intravenous infusion if necessary. This interven-
tion was performed in diabetic as well as non-diabetic patients.
Optimal oxygenation to avoid hypoxiawas achieved by performing
blood gas analysis during and after surgery.
2.5. SSI risk stratiﬁcation
Patients were evaluated by the preoperative and combined pre/
intraoperative risk scoring system described by Fowler et al.13 The
predicted risk for development of SSI in the two groups of patients
was calculated and compared.
2.6. Bacteriology
Screening for methicillin-resistant Staphylococcus aureus
(MRSA) was performed in all patients. Nasal, pharyngeal, and
inguinal areas were swabbed on the day of admission to hospital
and any strains of S. aureus isolated from swab cultureswere tested
for antibiotic susceptibility. ForMRSA-positive patientswith stable
angina, surgery was delayed while patients received intranasal
mupirocin therapy, daily chlorhexidine showers and, for those
with MRSA-positive throat swabs, topical application of chlorhex-
idine 0.2% for 3 days.
Generally, in cases with overt SSI, microbiological sampleswere
taken from the wound and cultured. In cases with a clinical
suspicion of deep SSI, blood cultureswere also taken. Sampleswere
cultured and organisms identiﬁed using standard microbiological
techniques.
2.7. Clinical endpoint
The study endpointwas freedom fromsuperﬁcial or deep SSI as
deﬁned by the Centers for Disease Control and Prevention
NationalNosocomial Infections Surveillance criteria.14 Superﬁcial
SSI was deﬁned as superﬁcial infection of the surgical site treated
with or without vacuum-assisted closure (VAC) therapy with
closed sternum before discharge and/or readmission within
30 days of surgery. Infection was documented by at least one of
the following: (1) surgical opening of the sternal wound with
excision of tissue (incision and drainage) and application of VAC
therapy; (2) positive bacterial culture(s); or (3) treatment with
antibiotics. Deep SSI was deﬁned as infection of the surgical site
treated with VAC therapy before discharge and/or readmission
within 30 days of surgery.
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The sample included all patients during the experimental
period who fulﬁlled the inclusion criteria. We calculated the
sample size needed to detect a statistical difference in the SSI rate
as compared to the known SSI rate. Based on this goal, a sample
size of 580 patients was required for this study to achieve 90%
power at the 5% signiﬁcance level (two-sided), allowing a 10%
drop-out rate of patients.15
2.9. Statistical analysis
Data were analyzed using SPSS software (version 13.0; IBM
SPSS, Chicago, IL, USA). Categorical variables were analyzed using
the Chi-square test. Continuous variables were analyzed with the
Student’s t-test.
3. Results
No additional adverse events were seen in the total patient
population except for the development of SSIs. Within the
microbial skin sealant group, no adverse events were observed
during follow-up. Patient follow-up was completed according to
the guidelines of the Centers for Disease Control and Prevention
National Nosocomial Infections Surveillance.14 There were no
drop-outs in this study.Table 1
Pre-, peri-, and postoperative characteristics of patients and surgery; data are n (%) un
Microbial skin sealant group (n=300)
Age (years), mean SD 65.18.6
Gender
Male 214 (71.3)
Female 86 (28.7)
Hyperlipidemia 220 (73.3)
Arterial hypertension 289 (96.3)
COPD 40 (13.3)
Diabetes mellitus 91 (30.3)
Peripheral artery disease 53 (17.7)
Carotid artery disease 48 (16)
Cardiovascular accident 33 (11)
Renal failure 41 (13.7)
LV ejection fraction, mean SD 48.113.4
Congestive heart failure 82 (27.3)
Acute myocardial infarction 109 (36.3)
Previous cardiac surgery
CABG 27 (9)
Valve replacement 51 (17)
Priority of procedure
Emergency 82 (27.3)
Urgent 13 (4.3)
Elective 205 (68.3)
Operative procedure
CABG 177 (59)
Valve surgery 56 (18.7)
Combined procedures 61 (20.3)
Other 6 (2)
Distal anastomoses, mean SD 2.4 0.9
LIMA graft 218 (72.7)
BIMA graft 15 (5)
Perfusion time
<100min 110 (36.7)
100–200min 184 (61.3)
>200min 6 (2)
SD, standard deviation; COPD, chronic obstructive pulmonary disease; LV, left ventricul
bilateral internal mammary artery.3.1. Patient and surgery characteristics
Characteristics of patients receiving microbial skin sealant
pretreatment (n = 300) and controls (n = 280) are shown in Table 1
Table 1. The mean age of the overall patient cohort was
66.8 8.6 years (range 30–95 years). In the control group there were
signiﬁcantly more patients suffering from hyperlipidemia (80.4% vs.
73.3%; p = 0.045). In general however, approximately three-quarters of
patients were hyperlipidemic and almost all were receiving treatment
for arterial hypertension. Signiﬁcantly more patients in the microbial
skin sealant group suffered from diabetes mellitus (30.3% vs. 21.1%;
p = 0.011),carotidarterydisease(16%vs.8.2%;p = 0.004),andcongestive
heart failure (27.3% vs. 18.2%; p = 0.009). Previous valve surgery was
more common among patients who received microbial skin sealant
pretreatment than among controls (17% vs. 7.1%; p < 0.001) (Table 1).
The pattern of surgery priority was similar in the two patient
groups; surgery was an urgent or emergency procedure in almost
one-third of the patients in both groups. Therewas a trend towards
less frequent use of the left internal mammary artery in patients
who received microbial skin sealant, which reﬂects the lower
incidence of left descending artery stenosis in this group. In
contrast, signiﬁcantly more patients pretreated with microbial
skin sealant received a bilateral internal mammary artery graft (5%
vs. 0.4%; p < 0.001) comparedwith the control group. The length of
CPB time in the two groups was similar, and was between 100 and
200 min in two-thirds of the cases.less otherwise indicated
Control group (n=280) p-Value for inter-group comparison
66.09.0 0.219
0.234
185 (66.1)
95 (33.9)
225 (80.4) 0.045
275 (98.2) 0.167
44 (15.7) 0.416
59 (21.1) 0.011
44 (15.7) 0.529
23 (8.2) 0.004
25 (8.9) 0.406
38 (13.6) 1.000
47.313.3 0.471
51 (18.2) 0.009
83 (29.6) 0.087
20 (7.1) 0.413
20 (7.1) <0.001
83 (29.6) 0.538
5 (1.8) 0.077
192 (68.6) 0.951
93 (33.2) <0.001
73 (26.1) 0.032
109 (38.9) <0.001
5 (1.8) 0.850
2.40.8 1.000
245 (87.5) 0.215
1 (0.4) <0.001
105 (37.5) 0.836
173 (61.8) 0.291
2 (0.7) 0.128
ar; CABG, coronary artery bypass graft; LIMA, left internal mammary artery; BIMA,
[(Figure_1)TD$FIG]
Figure 1. Incidence of surgical site infection (SSI) in patients undergoing cardiac
surgery who were treated with microbial skin sealant as part of preoperative skin
preparation and patients who received only standard preoperative preparation
(controls). The incidence of SSI was signiﬁcantly lower in the microbial skin sealant
group than in the control group (2.3% vs. 6.8%, p = 0.011).
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The preoperative risk score for SSI was 11.0  4.5 for the
microbial skin sealant group and 10.6  4.7 for the control group
(p = 0.293). The risk scores for SSI according to combined preopera-
tive–intraoperative factors were 9.8  4.0 and 8.6  3.7, respectively
(p < 0.001). The associated predicted risks for SSI were 3.5%
(preoperative) and 3.2% (combined) for the microbial skin sealant
group and 3.0% (preoperative) and 2.6% (combined) for the control
group.
3.3. Incidence of SSI
At the end of the study, SSI was recorded for 26 patients. Those
with SSI included seven patients in the microbial skin sealant
group (2.3%; onewith superﬁcial SSI and six with deep SSIs) and 19
patients in the control group (6.8%; 15 superﬁcial SSIs and four
deep SSIs). The inclusion of skin sealant in preoperative prepara-
tions resulted in a statistically signiﬁcant reduction in SSI
(p = 0.011) (Figure 1 Figure 1). Moreover, there was a 34% relative
risk reduction in SSIs observed in the microbial skin sealant group
compared with the SSI rate predicted by preoperative risk factors
(2.3% vs. 3.5%).
3.4. Bacteriology
All patients included in this study were free of MRSA during
screening. Among the 26 patients suffering from SSIs, woundTable 2
Isolated pathogens; data are n unless otherwise indicated
Microbial skin
sealant group
(n=300)
Control group
(n=280)
Methicillin-susceptible
Staphylococcus aureus
1 1
Methicillin-resistant
Staphylococcus aureus
2 1
Coagulase-negative Staphylococcus 1 5
Pseudomonas aeruginosa 2
Enterococcus faecalis 2
Klebsiella pneumoniae 1 1
Enterobacter cloacae 1cultures were positive in 18 cases (69.2%; Table 2). The most
commonly isolated pathogen was S. aureus, which caused ﬁve
(27.8%) of the microbiologically conﬁrmed SSIs, including three
cases ofMRSA. Other organisms obtained from sternal site samples
included Staphylococcus epidermidis (n = 6), Klebsiella pneumoniae
(n = 2), Enterococcus faecalis (n = 2), Pseudomonas aeruginosa
(n = 2), and Enterobacter cloacae (n = 1). The majority of patients
(61.1%) had a polymicrobial infection, and a monomicrobial
infection was seen in only seven of the 18 patients (38.9%) with
positive wound cultures. Blood cultures were positive in 13 of the
26 patients (50%) with SSI. All except one of those patients in the
microbial skin sealant group with SSI had positive blood cultures
and in three of these six patients (50%) positive blood cultureswere
found prior to microbiological conﬁrmation of sternal site
infection. In the control group, blood cultures were positive for
seven of the 12 patients (58.3%) with positive sternal site samples.
4. Discussion
Median sternotomy has become established as the standard
approach for most open cardiac surgery procedures since the
technique was introduced by Julian et al. in 1957.16 SSI is still a
serious potential complication of sternotomy that, with high
associated morbidity and mortality, leads to prolonged hospitali-
zation, repeated surgical procedures, and increased healthcare
costs.17–19 The development of a sternal SSI is a multifactorial
process. Numerous studies have identiﬁed a multitude of clinical
and perioperative variables as being contributory. A comparison of
rates of infection at the sternal site after cardiac surgery reported in
the literature is therefore difﬁcult, as different studies have
included patients with different characteristics undergoing sur-
gery involving different speciﬁc procedures. However, large
studies are helpful to analyze risk factors. For example, in a
multivariate logistic regression analysis of more than 9000
consecutive adult patients undergoing full sternotomy, Gummert
et al.20 showed that the presence of diabetes, use of single or
bilateral internal mammary artery graft(s), intensive care unit stay
of more than 5 days, re-exploration, and BMI >30 kg/m2,
signiﬁcantly increased the risk of a deep SSI. Old age and the
presence of COPD and renal failure are also established risk factors
for SSI.21–24
In this study, patients in the two treatment groups were of
similarmean age, and similar proportions of patients in each group
were suffering from COPD and renal failure. In contrast, a
signiﬁcantly higher proportion of patients in the skin sealant
group than in the control group had diabetes mellitus (30.3% vs.
21.1%; p < 0.011), and both internal mammary arteries were used
in signiﬁcantly more patients in the skin sealant group compared
with the control group (5% vs. 0.4%; p < 0.001). Such inter-group
differences in important risk factors for SSI suggest that one group
might be at higher risk than the other. We therefore evaluated risk
factors and calculated the predicted rate of SSI of both groups using
the risk stratiﬁcation system of Fowler et al.13 According to pre-
operative risk scores, both patient groups were at similar risk of
developing SSI. The combined risk score based on pre- and
intraoperative variables showed a higher risk for SSI in the skin
sealant group compared with the control group. This appears to
reﬂect longer CPB times and more frequent intraoperative
application of an intra-aortic balloon pump in the skin sealant
group. Although each of these factors alone did not differ
signiﬁcantly between groups, their combined effect had a greater
impact on the risk score in this risk evaluation system. Notably,
despite the similar (preoperative) or increased (combined) risk in
the microbial skin sealant group, use of this adjunct to preopera-
tive skin preparation signiﬁcantly reduced the observed incidence
of SSI to a rate corresponding to a third lower than that predicted
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frequency of SSI observed in the control group, which was more
than two-fold higher than predicted, suggests that the risk scoring
systemmay have underestimated SSI risk in this series of patients.
The risk of developing SSI after surgery depends in part on the
‘dose’ of bacterial contamination, i.e., the number of bacteria that
colonize the surgical wound.14 While the operative wound
following cardiac surgery is considered to be ‘clean’,14 the surgical
site may be contaminated by airborne bacteria-carrying particles
in the operating room and intensive care unit, by bacteria from
endogenous sources such as the patient’s mucousmembranes that
are spread on the hands of theatre personnel, or by direct
contamination by the patient’s normal skin microﬂora. Patients
included in this study were operated on at the same clinical centre
by the same surgeon, thereby minimizing differences in medical
environment, preoperative preparation, surgical technique, and
postoperative care that are likely to occur in a multicenter study.
On the other hand, ‘standard’ techniques and the clinical practice
of individual clinical staff may have changed during the 31-month
period in which the data were collected, which is a limitation of
this study. The number of patients and the duration of the study
should, however, have limited any effect of seasonal differences on
the SSI risk of the two treatment groups. Additional studies have
been initiated to collect data during equivalent periods. Although
this was not a randomized comparison, which represents a further
limitation, the data were collected from patients undergoing
routine operations carried out in a cardiovascular surgery unit and
are thus more representative of clinical reality.
In this study, the bacterial species isolated most commonly
from sternal wound SSI were S. aureus and S. epidermidis. Sternal
infection with S. aureus in particular is associated with serious
morbidity, high mortality, and a poor prognosis.25,26 Coagulase-
negative staphylococci are also major pathogens in sternal
infections, particularly when implanted material is intro-
duced.24,27,28 Importantly, the endogenous route of SSI after
cardiac surgery has been demonstrated for both S. aureus and
coagulase-negative staphylococci.27,28 In some patients, the strain
of S. aureus isolated from surgical wound infections following
cardiac surgery has been shown to be identical to that colonizing
the nose,29,30 but the majority of such infections are likely to be
caused by staphylococci and other species of the patient’s skin
microﬂora.14,28,31Microbiological screening showed the absence of
MRSA in this patient population, and decolonization of carriers
prior to surgery was not required. Although colonization at
admission may have been undetected and thus cannot be
excluded, the ﬁnding of MRSA isolated from the sternal SSI in
three patients is consistent with nosocomial rather than endoge-
nous transmission, as reported elsewhere.30 Given the predomi-
nant role of the skin microbial ﬂora in SSI, inhibiting the migration
of endogenous potential pathogens appears to be a rational
approach to reducing surgical wound contamination. Important
advantages of this approach to immobilizing all skin-borne
microorganisms in situ is that it targets all types of pathogen
and does not promote the common mechanisms of bacterial
resistance to antibiotics.
Pretreatment with the skin sealant is convenient and its use has
been easily integrated with existing routine preoperative pre-
parations used at this surgical centre. No cases of skin sensitivity or
other reaction following application of the skin sealant were noted
and it can be used safely after a variety of skin preparation
solutions and without the need for a speciﬁc wound closure
technique.
In conclusion, this comparison of outcomes from a single
surgeon’s patients shows that including a microbial skin sealant
prior to cardiac surgery signiﬁcantly reduced the rate of SSI. The
skin sealant may thus be a useful addition to the multimodalprevention approach needed to minimize bacterial contamination
of surgical incisions.
4.1. Study limitations
This study is limited by the fact that it was a single center, non-
randomized, retrospective study. Furthermore the patient char-
acteristics were not identical for both groups and therefore
patients were at different risk of developing an SSI. However, in
this study we were able to see a signiﬁcant reduction in SSI even
though the microbial skin sealant group was at higher risk of
developing an SSI. To date there are no other data available for the
reader on this microbial skin sealant to determine the value of this
additional tool except for a prospective, randomized, multicenter
clinical trial in patients undergoing an open inguinal hernia
repair.8
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